How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214

calendar_today May 27, 2026 person Stef Gesuero domain cartography-biosciences
The post A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 appeared first on Cartography Biosciences .
open_in_new Read original post